LEADER 01110cam a22002777i 4500 001 991000752139707536 008 050117s2000 enka b 001 0 eng d 020 $a0340759097 035 $ab13267541-39ule_inst 040 $aDip.to Di.S.Te.B.A.$beng 082 00$a614.5$221 245 00$aMolecular epidemiology of infectious diseases /$cedited by R. C. Andrew Thompson 260 $aLondon :$bArnold ;$aNew York :$bOxford University Press,$c2000 300 $aviii, 326 p. :$bill. ;$c28 cm 504 $aIncludes bibliographical references and index 650 0$aCommunicable diseases$xEpidemiology 650 0$aMolecular epidemiology 650 12$aCommunicable Diseases$xEpidemiology 650 22$aEpidemiologic Methods 700 1 $aThompson, R. C. A. 907 $a.b13267541$b21-09-06$c17-01-05 912 $a991000752139707536 945 $aLE003 614.5 THO01.01 (2000)$g1$i2003000098228$lle003$o-$pE126.43$q-$rl$s- $t0$u2$v20$w2$x0$y.i13985395$z17-01-05 996 $aMolecular epidemiology of infectious diseases$91106488 997 $aUNISALENTO 998 $ale003$b17-01-05$cm$da $e-$feng$genk$h0$i0 LEADER 05635nam 2200637Ia 450 001 9910953923303321 005 20251117080343.0 010 $a1-61761-167-0 035 $a(CKB)2670000000150170 035 $a(EBL)3017989 035 $a(SSID)ssj0000694155 035 $a(PQKBManifestationID)11368968 035 $a(PQKBTitleCode)TC0000694155 035 $a(PQKBWorkID)10667230 035 $a(PQKB)11551206 035 $a(MiAaPQ)EBC3017989 035 $a(Au-PeEL)EBL3017989 035 $a(CaPaEBR)ebr10658911 035 $a(OCoLC)775352327 035 $a(BIP)31070744 035 $a(EXLCZ)992670000000150170 100 $a20100625d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aVentricular fibrillation and acute coronary syndrome /$feditor, Joyce E. Mandell 205 $a1st ed. 210 $aHauppauge, NY $cNova Science$d2011 215 $a1 online resource (248 p.) 225 1 $aCardiology research and clinical developments 300 $aDescription based upon print version of record. 311 08$a1-61728-969-8 320 $aIncludes bibliographical references and index. 327 $a""VENTRICULAR FIBRILLATION AND ACUTE CORONARY SYNDROME""; ""VENTRICULAR FIBRILLATION AND ACUTE CORONARY SYNDROME""; ""CONTENTS ""; ""PREFACE""; ""CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME: CLINICAL IMPLICATIONS AND EMERGING THERAPIES ""; ""ABSTRACT ""; ""ABBREVIATIONS LIST ""; ""INTRODUCTION ""; ""RESISTANCE/VARIABLE RESPONSE TO CLOPIDOGREL. DOES IT EXIST? ""; ""MECHANISMS OF VARIABLE RESPONSE TO CLOPIDOGREL ""; ""Genetic Polymorphism ""; ""Drug-Drug Interactions ""; ""Statins ""; ""Proton Pump Inhibitors ""; ""Calcium-Channel Blockers "" 327 $a""IS IT POSSIBLE TO ACCURATELY ASSESS THE INHIBITORY EFFECT OF ANTIPLATELT DRUGS? """"CLINICAL IMPLICATIONS OF VARIABLE RESPONSE TO CLOPIDOGREL ""; ""Drug Eluting Stent""; ""WHAT TO DO WITH PATIENTS WITH REDUCED RESPONSE TO CLOPIDOGREL THERAPY? ""; ""Optimise Clopidogrel Response According to Platelet Function Tests ""; ""EMERGING THERAPIES ""; ""Prasugrel ""; ""Ticagrelor ""; ""Cangrelor ""; ""REFERENCES ""; ""PROTEOMICS OF ACUTE CORONARY SYNDROME ""; ""1. INTRODUCTION ""; ""2. PLASMA ""; ""3. BLOOD CELLS IN ACUTE CORONARY SYNDROME ""; ""3.1. Circulating Monocytes ""; ""3.2 Platelets "" 327 $a""3.3. Proteomics on Vascular Progenitors """"Endothelial Progenitor Cells (EPC) ""; ""4. TISSUE PROTEOMICS ""; ""Secretome ""; ""5. METABOLOMICS""; ""ABBREVIATIONS""; ""PROTEINS ABBREVIATIONS ""; ""REFERENCES ""; ""MAJOR BLEEDING IN ACUTE CORONARY SYNDROME: DEFINITIONS, MAGNITUDE OF THE PROBLEM, PREDICTORS, OUTCOMES, MANAGEMENT, AND PREVENTION ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""DEFINITIONS OF MAJOR BLEEDING IN ACS ""; ""MAGNITUDE OF THE PROBLEM ""; ""PREDICTORS OF MAJOR BLEEDING ""; ""Age ""; ""Gender ""; ""History of Bleeding ""; ""Renal Impairment ""; ""Type of ACS "" 327 $a""Killip Class """"Diabetes Mellitus ""; ""Choice of Antiplatelet, Antithrombotic, and Fibrinolytic Agents""; ""Invasive Procedures ""; ""Blood Transfusion ""; ""Anemia ""; ""HOSPITAL OUTCOMES AND MAJOR BLEEDING ""; ""Mechanisms by Which Major Bleeding Affects Outcomes ""; ""Prevention and Management ""; ""CONCLUSION ""; ""REFERENCES""; ""NOVEL ANTIPLATELETS IN ACUTE CORONARY SYNDROMES ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""ASPIRIN (ACETYLSALICYLIC ACID, ASA) ""; ""THIENOPYRIDINES ""; ""Ticlopidine ""; ""Clopidogrel ""; ""Prasugrel ""; ""Cangrelor (ARC-69931MX) ""; ""Ticagrelor (AZD6140) "" 327 $a""Elinogrel """"Bx667 ""; ""THROMBOXANE RECEPTOR ANTAGONISTS ""; ""Terutroban (S18886) ""; ""von Willebrand Factor Inhibitors ""; ""Ajw200 ""; ""Arc1779 ""; ""Alx-0081 ""; ""DIRECT THROMBIN INHIBITORS (PAR-1 INHIBITORS) ""; ""Sch 530348 ""; ""E5555 ""; ""CONCLUSION ""; ""REFERENCES ""; ""UNCONTROLLED IMMUNE RESPONSE IN ACUTE MYOCARDIAL INFARCTION ""; ""ABSTRACT""; ""INTRODUCTION ""; ""LEUKOCYTES ""; ""NEUTROPHILS ""; ""MONOCYTES ""; ""LYMPHOCYTES ""; ""Rationale and Clinical Evidence ""; ""Effector T-Cells ""; ""Regulatory T-Cells ""; ""The Inverted Pyramid Model "" 327 $a""THERAPEUTIC OPPORTUNITIES "" 330 $aVentricular fibrillation is a cause of cardiac arrest and sudden cardiac death. The ventricular muscle twitches randomly, rather than contracting in a co-ordinated fashion (from the apex of the heart to the outflow of the ventricles), and so the ventricles fail to pump blood into the arteries and into systemic circulation. Ventricular fibrillation is a sudden lethal arrhythmia responsible for many deaths mostly brought on by ischaemic heart disease. Acute coronary syndrome (ACS) is a set of signs and symptoms related to the heart. ACS is compatible with a diagnosis of acute myocardial ischemia. This book presents current research from across the globe in the study of ventricular fibrillation and acute coronary syndrome, including clopidogrel response in acute coronary syndrome; primary ventricular fibrillation in "tako-tsubo" syndrome; and ECG predictors of fibrillatory events. 410 0$aCardiology research and clinical developments. 606 $aCoronary heart disease 606 $aVentricular fibrillation 615 0$aCoronary heart disease. 615 0$aVentricular fibrillation. 676 $a616.1/23 701 $aMandell$b Joyce E$01863883 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910953923303321 996 $aVentricular fibrillation and acute coronary syndrome$94470579 997 $aUNINA